Abstract
Butterfly Network Inc will report its first-quarter 2026 results on April 30, 2026 Pre-Market; this preview outlines expectations for revenue of 26.07 million US dollars (+23.22% year over year), an estimated EBIT of approximately -17.53 million US dollars, EPS near -0.07, and the key drivers that could guide management’s commentary and the stock’s reaction.Market Forecast
The market’s baseline for Butterfly Network Inc this quarter centers on revenue of 26.07 million US dollars, implying 23.22% year-over-year growth, an EPS loss of about -0.07 with a 19.99% year-over-year improvement, and EBIT around -17.53 million US dollars with a 9.05% year-over-year improvement; forecasts for gross margin or net margin are not specified. Based on the company’s recent trend, gross margin has been anchored in the high-60% range, and investors will look for commentary on whether mix and pricing can sustain this level as volume normalizes from seasonal Q4 strength.Butterfly Network Inc’s commercial engine is led by hardware device sales augmented by connected software and services; the company’s disclosed revenue structure indicates approximately 65% from products and 35% from software and other services, underpinning a high gross-margin profile and growing recurring revenue attachment. Among its businesses, software and services carry the clearest expansion runway supported by new AI-enabled features; revenues for this stream were recently reported at 34.17 million US dollars, and management’s qualitative outlook suggests continued attach-rate gains even as device sales remain the entry point.
Last Quarter Review
In the prior quarter, Butterfly Network Inc delivered revenue of 31.51 million US dollars, a 41.00% year-over-year increase, with gross profit margin of 67.34%, a GAAP net loss attributable to shareholders of 15.29 million US dollars and a net profit margin of -48.52%, while adjusted EPS was approximately -0.02 per share. The company’s net result improved sequentially, with quarter-on-quarter net profit growth of 54.99%, reflecting operating leverage as volumes scaled and cost controls held.Operationally, the company exceeded revenue expectations and provided a confident full-year 2026 outlook of 117.00–121.00 million US dollars, framing a path of double-digit growth and signaling demand resilience across customer cohorts. In terms of business mix, products accounted for 63.44 million US dollars and software and other services for 34.17 million US dollars on the most recently disclosed basis, with the latter deepening engagement and enhancing lifetime value across the installed base.
Current Quarter Outlook
Main business: Devices and connected ecosystem execution
Butterfly Network Inc’s core revenue driver remains the shipment of handheld ultrasound devices integrated with its cloud-connected workflow. The current-quarter revenue estimate of 26.07 million US dollars implies a typical seasonal step-down from the fourth quarter’s 31.51 million US dollars while registering a 23.22% year-over-year increase, a combination that underscores healthy demand against a tougher sequential comparison. Expect management to discuss ordering cadence across health systems, education channels, and international distributors, alongside pricing and promotional activity that can influence realized average selling prices and gross margin.While gross margin guidance for the quarter is not specified, last quarter’s 67.34% level provides a reference point for investors evaluating the device-versus-software mix. Hardware shipments carry lower margin than cloud and services, but they are the on-ramp to expanding account penetration and subscription adoption; the trade-off tends to be favorable when hardware growth coincides with higher attach rates. A focal point for the call will be whether order pipelines seen in late 2025 and early 2026 are translating into shipments in the current period and how new account wins or expansions are pacing against internal targets.
Another element that can influence device momentum is inventory at channel partners and institutional customers. If Q4 saw accelerated purchasing to meet budget timelines, Q1 can reflect digestion, shifting some revenue recognition into later quarters. Even with this dynamic, the market’s expectation for a 23.22% year-over-year increase suggests that unit and price/mix are sufficient to offset seasonality, reinforcing the view that the installed base is broadening. Management commentary on funnel quality, sales cycle duration, and enterprise rollouts will be crucial for gauging how quickly the hardware footprint can scale through 2026 under the full-year revenue framework of 117.00–121.00 million US dollars.
Most promising business: Software subscriptions and AI-enabled tools
Software and services, representing approximately 35% of the most recently disclosed revenue structure at 34.17 million US dollars, appear positioned to drive incremental margin and valuation leverage. The introduction of new AI-assisted capabilities, including a fully automated gestational age tool that has gained regulatory clearance, broadens clinical utility and should support higher attachment to devices over time. These features deepen the value proposition for existing accounts and can accelerate expansion within departments and care settings where rapid, standardized measurements reduce workflow friction and training barriers.From a financial perspective, software and services typically deliver higher gross margins than hardware, which can help sustain consolidated margin even when the quarter’s mix leans toward device shipments. Investors will be attuned to metrics and commentary around subscription adoption, churn, and dollar-based expansion. If attach rates and usage intensity continue to climb, recurring revenue growth can outpace hardware, smoothing seasonality and strengthening visibility into cash generation as the company narrows losses.
This quarter, expect attention on how quickly AI features transition from pilots to paid deployments and on early feedback from clinical teams. Any color on international utilization, where the company has highlighted early deployments and training programs, will also inform the scalability of the software model across markets with varying infrastructure and payment dynamics. The cadence of product updates, integration with third-party systems, and the breadth of automated measurements could become leading indicators of expansion in both average revenue per user and total software subscribers through the year.
Key stock-price drivers: Loss trajectory, operating leverage, and 2026 revenue framework
The path to profitability remains the central driver for investor sentiment. The quarter’s estimated EBIT loss of about -17.53 million US dollars implies a 9.05% year-over-year improvement, aligning with the company’s message of disciplined expense control as revenue grows. If management quantifies continued operating leverage—particularly in sales and marketing efficiency and in R&D scaling relative to revenue—investors may gain confidence that losses can continue to narrow over the next few quarters without sacrificing product velocity.Guidance and commentary around the full-year revenue framework will likely have an outsized impact on the stock. The previously communicated 2026 revenue target of 117.00–121.00 million US dollars sits ahead of the consensus that prevailed earlier in the year and suggests management has visibility into pipelines and enterprise activity. Reaffirmation of this range, or refined quarterly phasing, would help reconcile a seasonally softer first quarter with the implied acceleration later in the year. Investors will listen for signals on the second-half weighting, any large account implementations, and the balance between North America and international contributions.
A secondary but important stock-price variable is regulatory and product milestone momentum. The clearance of automated clinical tools not only enhances the narrative on innovation but also can influence account-level economics as customers justify broader deployment. Any incremental product approvals, mode expansions, or workflow integrations discussed this quarter could lift medium-term growth expectations for software and, by extension, blended gross margin. Conversely, if the company indicates elongated approval timelines or slower-than-expected customer validation cycles for newly launched features, near-term revenue mix may skew more toward hardware, with implications for margin cadence and operating losses.
Analyst Opinions
Across the most recent six-month window, published views on Butterfly Network Inc skew decisively positive, with a 100% bullish ratio among covered notes identified and no flagged bearish ratings, indicating a constructive stance into the April 30, 2026 report. Notably, Lake Street has reiterated its Buy rating and, in a recent update, set a price target as high as 5.50 US dollars, following a prior communication that reaffirmed a 4.00 US dollars target; the continuity of the Buy recommendation underscores confidence in the company’s execution and forward revenue framework. Craig-Hallum has also maintained a Buy rating, emphasizing the company’s momentum in operational performance and its upside potential from software-driven monetization.The majority view centers on three pillars. First, revenue acceleration appears to be taking hold, evidenced by a 41.00% year-over-year increase in the fourth quarter and a current-quarter projection of 23.22% year-over-year growth. This pattern is seen as a validation of underlying demand and sales productivity and supports the company’s full-year 2026 revenue range of 117.00–121.00 million US dollars. Analysts leaning bullish point to the company’s outperformance versus prior quarterly revenue expectations as indicative of growing traction in key customer segments and of execution consistency in channel strategy and account expansion.
Second, margin quality and operating efficiency are viewed as sustainably improving. The 67.34% gross margin posted in the last quarter provides a foundation for sustaining high-60s margins as long as software and services keep expanding their contribution and hardware pricing remains stable. The expected 9.05% year-over-year improvement in EBIT this quarter is consistent with the thesis that expense discipline, particularly in go-to-market and R&D allocation, can allow the company to scale into its cost base. Bullish analysts expect losses to continue narrowing through 2026, with the revenue mix shift and recurring software revenue supporting both gross margin and operating leverage.
Third, product catalysts—especially in AI-assisted capabilities—are seen as incremental demand drivers that can enhance average revenue per customer and adoption speed. The recent regulatory clearance of an automated gestational age tool is cited as a proof point of the platform’s pace of innovation and its appeal in settings where speed and standardization matter. Analysts highlighting these developments anticipate stronger software attachment over time, potentially leading to higher lifetime value per device sold and more predictable revenue. This line of reasoning dovetails with the bullish view that software and services can outgrow hardware in the medium term, improving the company’s margin structure and valuation narrative.
On balance, the dominant institutional stance projects constructive near-term and medium-term outcomes: a solid year-over-year revenue increase this quarter, narrowing losses consistent with improving operating leverage, and an innovation roadmap capable of elevating recurring revenue metrics. For the April 30, 2026 Pre-Market report, the bullish camp will be looking for validation on three fronts—meeting or exceeding the 26.07 million US dollars revenue estimate and the -0.07 EPS trajectory, reiterating or refining the 117.00–121.00 million US dollars full-year revenue framework, and providing tangible evidence that AI-enabled software features are translating into higher attach rates and account expansion. A positive readout on these items would, in the bullish view, reinforce the momentum established exiting 2025 and set the stage for an improved balance between growth and profitability through the remainder of 2026.
Comments